Mostrar el registro sencillo del ítem

dc.rights.licenseLicencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacionalspa
dc.contributor.authorBermúdez, Valmore
dc.contributor.authorRojas-Quintero, Joselyn
dc.contributor.authorVelasco, Manuel
dc.description.abstractespite the monumental efforts directed into studying and describing the pathways, factors, genetic predisposition, and target-specific pharmacotherapy to atherosclerosis, ischemic heart disease, thrombotic cerebrovascular disease and peripheral artery disease are still responsible for 50% of all the deaths occurring in the developed world. The quest for a clear pathophysiology into atherosclerosis began with von Rokitansky’s incrustation theory, which evolved into the crucial role of platelets and thrombogenesis during acute coronary syndromes (1). Next, came the irritation theory postulated by Virchow, which detailed the presence of leukocytes in atherosclerotic plaques, suggesting the presence of chronic inflammation and progressive vessel deformation (1). By 1904, the term atherosclerosis was coined by Felix Jacob Marchand and 9 years later Nikolai Anichkov published that cholesterol alone can induce the vascular changes associated with atherosclerosis (1). The impeccable work performed by Anichkov and his team, paved the way to the current understanding and clinical logic used in current cardiovascular medicine (the lipid hypothesis), which for the longest period focused mainly in plasma lipids as sole culprits for atherogenesis. Genetic connection between cholesterol and heart disease came in 1939, when Müller described families with severe hypercholesterolemia and early onset cardiac disease and death (2). The recognition of hereditary hyperlipidemias and their characteristics, cemented the role on cholesterol in cardiovascular risk, along with the findings from the epidemiological mammoth, the Framingham Heart Study (3). At some point, the lipid hypothesis was “universally recognized as a law” [2002] (4), and as such, it dominated pharmacotherapy development in cardiovascular
dc.publisherAME Publishing Companyeng
dc.sourceJournal Of Thoracic Diseaseeng
dc.sourceVol. 10, No.1 (2018)spa
dc.subjectMighty cholesteroleng
dc.subjectIschemic heart diseaseeng
dc.subjectThrombotic cerebrovascular diseaseeng
dc.subjectPeripheral arteryeng
dc.titleThe quest for immunotherapy in atherosclerosis: CANTOS study, interleukin-1β and vascular inflammationeng
dcterms.bibliographicCitationCapron L. Pathogenesis of atherosclerosis: an update on the three main theories. Ann Cardiol Angeiol (Paris) 1989;38:631-4.eng
dcterms.bibliographicCitationMüller C. Angina pectoris in hereditary xanthomatosis. Arch Intern Med 1939;64:675-700.eng
dcterms.bibliographicCitationWilson PW, Garrison RJ, Castelli WP, et al. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol 1980;46:649-54.eng
dcterms.bibliographicCitationThompson GR, Packard CJ, Stone NJ. Goals of statin therapy: three viewpoints. Curr Atheroscler Rep 2002;4:26-33.eng
dcterms.bibliographicCitationBertrand MJ, Tardif JC. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. Expert Opin Emerg Drugs 2017;22:1-26.eng
dcterms.bibliographicCitationDuBroff R, de Lorgeril M. Cholesterol confusion and statin controversy. World J Cardiol 2015;7:404-9.eng
dcterms.bibliographicCitationEsselstyn CB. A plant-based diet and coronary artery disease: a mandate for effective therapy. J Geriatr Cardiol 2017;14:317-20.eng
dcterms.bibliographicCitationVoight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380:572-80.eng
dcterms.bibliographicCitationNakaya K, Ikewaki K. Microbiota and HDL metabolism. Curr Opin Lipidol 2018;29:18-23.eng
dcterms.bibliographicCitationGovea-Alonso DO, Beltrán-López J, Salazar-González JA, et al. Progress and future opportunities in the development of vaccines against atherosclerosis. Expert Rev Vaccines 2017;16:337-50.eng
dcterms.bibliographicCitationMatsuura E, Atzeni F, Sarzi-Puttini P, et al. Is atherosclerosis an autoimmune disease? BMC Med 2014;12:47.eng
dcterms.bibliographicCitationVecchione C, Gentile MT, Aretini A, et al. A novel mechanism of action for statins against diabetes-induced oxidative stress. Diabetologia 2007;50:874-80.eng
dcterms.bibliographicCitationRoss R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999;340:115-26.eng
dcterms.bibliographicCitationZhou X, Paulsson G, Stemme S, et al. Hypercholesterolemia is associated with a T helper (Th) 1/ Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 1998;101:1717-25.eng
dcterms.bibliographicCitationRojas J. Inflammasomes – Fighting the enemy from within. Avan Biomed 2012;1:18-29.eng
dcterms.bibliographicCitationWeber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal 2010;3:cm1.eng
dcterms.bibliographicCitationRidker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomized controlled trial. Lancet 2017. [Epub ahead of print].eng
dcterms.bibliographicCitationBorovac JA, D’Amario D, Niccoli G . Neoatherosclerosis and late thrombosis after percutaneous coronary intervention: translational cardiology and comparative medicine from bench to bedside. Yale J Biol Med 2017;90:463-70.eng
dcterms.bibliographicCitationSalazar J, Luzardo E, Mejías JC, et al. Epicardial Fat: physiological, pathological and therapeutic implications. Cardiol Res Pract 2016;2016:1291537.eng
dcterms.bibliographicCitationBermúdez V, Rojas J, Salazar J, et al. Sensitivity and Specificity Improvement in Abdominal Obesity Diagnosis Using Cluster Analysis during Waist Circumference Cut- Off Point Selection. J Diabetes Res 2015;2015:750265.eng
dcterms.bibliographicCitationAbbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University- Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol 2013;111:1394-400.eng
dcterms.bibliographicCitationChyu KY, Dimayuga PC, Shah PK. Vaccine against arteriosclerosis: an update. Ther Adv Vaccines 2017;5:39-47.eng
dcterms.bibliographicCitationTourani M, Karkhah A, Najafi A. Development of an epitope-based vaccine inhibiting immune cells rolling and migration against atherosclerosis using in silico approaches. Comput Biol Chem 2017;70:156-63.eng
dcterms.bibliographicCitationMao D, Kai G, Gaofu Q, et al. Intramuscular immunization with a DNA vaccine encoding a 26-amino acid CETP epitope displayed by HBc protein and containing CpG DNA inhibits atherosclerosis in a rabbit model of atherosclerosis. Vaccine 2006;24:4942-50.eng

Ficheros en el ítem


No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

  • Artículos
    Artículos científicos evaluados por pares

Mostrar el registro sencillo del ítem